Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate cancer center director, Experimental Therapeutics, Yale School of Medicine, discusses the importance of clinical trial enrollment for patients with 

-amplified dedifferentiated liposarcoma, enrolling them in a clinical trial for an MDM2 inhibitor, such as BI 907828, at a site that has a clinical trial opened, would be an ideal treatment approach, LoRusso explains. BI 907828 is an important drug for this particular tumor type with an 

 alteration, LoRusso adds. Moreover, BI 907828 demonstrated efficacy in a prior phase 1 trial (NCT03449381), and the soft tissue sarcoma community should be alerted to this drug, LoRusso says. 

BI 907828 is now under further investigation in the phase 2/3 Brightline-1 trial (NCT05218499) in patients with dedifferentiated liposarcoma. Patients with this 

 amplifications could benefit from enrollment, LoRusso concludes. 

Videos

Patricia LoRusso, DO, discusses the importance clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.


Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated Liposarcoma

Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate cancer center director, Experimental Therapeutics, Yale School of Medicine, discusses the efficacy observed of BI 907828 in solid tumors in a phase 1 trial (NCT03449381).

This study evaluated adult patients with different types of advanced solid tumors to find the preferred dose of BI 907828.

Results from this trial showed patients achieved responses and a prolongation of stable disease, LoRusso says. Notably, the responses observed were durable, LoRusso adds.

In patients with MDM2 amplification, BI 907828 generated responses, regardless of the dosage administered or the schedule of treatment, LoRusso adds.

The low dose and high dose of BI 907828 will be further explored in the phase 2/3 Brightline-1 trial (NCT05218499) in patients with dedifferentiated liposarcoma, LoRusso concludes.

Patricia LoRusso, DO, discusses the efficacy observed of BI 907828 in solid tumors in a phase 1 trial.


Dr. LoRusso on the Efficacy of BI 907828 in Solid Tumors

Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate director, Innovative Medicine, Yale Cancer Center, discusses the role of PARP inhibitors in triple negative breast cancer (TNBC).

PARP inhibitors are extremely important in 

-mutant disease, explains LoRusso. Studies evaluating their role in ovarian cancer have shown that PARP inhibitors can significantly increase the effectiveness of targeted agents.

Prior chemotherapy exposure, even in the adjuvant setting, can actually hinder the efficacy of PARP inhibitors by altering the 

 mutation and thus restoring the tumor's ability to undergo homologous recombination and repair, says LoRusso.

Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate director, Innovative Medicine, Yale Cancer Center, discusses the role of PARP inhibitors in triple negative breast cancer.

Patricia LoRusso, DO

Articles

Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated Liposarcoma

Dr. LoRusso on the Efficacy of BI 907828 in Solid Tumors

Dr. LoRusso on PARP Inhibitors in Triple-Negative Breast Cancer